Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride)
(Synonyms: 丙酰左旋肉碱盐酸盐; L-Propionylcarnitine chloride; ST-261) 目录号 : GC30373
Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride)是一种天然存在的肉碱衍生物，由肉碱乙酰转移酶在不饱和链脂肪酸的β氧化过程中生成，具有治疗多种心血管疾病、肾功能恶化、间歇性跛行及其他疾病的潜力。
Cas No.:119793-66-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride) is a naturally occurring carnitine derivative formed by carnitine acetyltransferase during β-oxidation of uneven chain fatty acids, which has therapeutic potential for the treatment of various cardiovascular disorders, kidney function deterioration, intermittent claudication, and other diseases[1][2].
In vitro, Levocarnitine propionate hydrochloride (1mM) incubation on human umbilical vein endothelial cells (HUVECs) for 4-72h reduced the production of reactive oxygen species (ROS) and Increased proliferation and iNOS expression[3]. Levocarnitine propionate hydrochloride (10-6, 10-7 and 10-8M) treatment on isolated rabbit heart 30min before ischemia reduced mitochondrial dysfunction induced by ischemia, preventing mitochondrial calcium overload, and depletion of ATP tissue stores[4].
In vivo, Levocarnitine propionate hydrochloride (10mg/rabbit) intramuscularly injected into rabbit model of hind limb ischemia increased the rate of revascularization and the hind limb vascular area[3].
References:
[1] Tama B, Fabara S P, Zarrate D, Sohail A A. Effectiveness of Propionyl-L-Carnitine Supplementation on Exercise Performance in Intermittent Claudication: A Systematic Review. Cureus. 2021 Aug 31;13(8):e17592.
[2] Pace S, Longo A, Toon S, Rolan P, Evans A M. Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption.Br J Clin Pharmacol. 2000 Nov;50(5):441-8.
[3] Stasi M A, Scioli M G, Arcuri G, et al. Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):426-35.
[4] Ferrari R, Ceconi C, Cargnoni A, et al. The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria.Cardiovasc Drugs Ther. 1991 Feb:5 Suppl 1:57-65.
Levocarnitine propionate hydrochloride (L-Propionylcarnitine chloride)是一种天然存在的肉碱衍生物，由肉碱乙酰转移酶在不饱和链脂肪酸的β氧化过程中生成，具有治疗多种心血管疾病、肾功能恶化、间歇性跛行及其他疾病的潜力[1][2]。
体外实验中，Levocarnitine propionate hydrochloride（1mM）处理人脐静脉内皮细胞（HUVECs）4–72h，可减少活性氧（ROS）产生，促进细胞增殖并诱导型一氧化氮合酶（iNOS）表达[3]；Levocarnitine propionate hydrochloride（10⁻⁶、10⁻⁷及10⁻⁸M）在离体兔心脏于缺血前30min灌注，可减轻缺血诱导的线粒体功能障碍，防止线粒体钙超载及ATP组织储备耗竭[4]。
体内实验中，Levocarnitine propionate hydrochloride（10mg/兔）于兔后肢缺血模型肌内注射，可显著提高再血管化速率并扩大后肢血管面积[3]。
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVEC) |
Preparation Method | Confluent HUVEC were treated with Levocarnitine propionate hydrochloride at a 1mM concentration. |
Reaction Conditions | 1mM; 4-72h |
Applications | Levocarnitine propionate hydrochloride reduced the production of reactive oxygen species (ROS), increased proliferation and iNOS expression and downregulated Nox4, Nox2, and ICAM-1. |
| Animal experiment [1]: | |
Animal models | New Zealand rabbits |
Preparation Method | Unilateral hind limb ischemia was performed by left femoral artery excision in New Zealand rabbits. After 3 days, Levocarnitine propionate hydrochloride was injected in 1mL saline (10mg/rabbit) into 3 points of the quadriceps muscle. |
Dosage form | 10mg; intramuscular injection; once injection |
Applications | Levocarnitine propionate hydrochloride increased the rate of revascularization and the hind limb vascular area. |
References: | |
| Cas No. | 119793-66-7 | SDF | |
| 别名 | 丙酰左旋肉碱盐酸盐; L-Propionylcarnitine chloride; ST-261 | ||
| Canonical SMILES | CCC(O[C@H](CC(O)=O)C[N+](C)(C)C)=O.[Cl-] | ||
| 分子式 | C10H20ClNO4 | 分子量 | 253.72 |
| 溶解度 | DMSO : 150 mg/mL (591.20 mM);Water : 60 mg/mL (236.48 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9414 mL | 19.7068 mL | 39.4135 mL |
| 5 mM | 788.3 μL | 3.9414 mL | 7.8827 mL |
| 10 mM | 394.1 μL | 1.9707 mL | 3.9414 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet